Pamela L. Zeitlin, MD, MPhil, PhD Make an Appointment Ask a Question Refer Patient Pamela L. Zeitlin, MD, is a pediatric pulmonologist at National Jewish Health. Dr. Zeitlin serves as Chair of the Department of Pediatrics. Silverstein Chair, Department of Pediatrics Professor of Pediatrics 5280 Top Doctors 2021 Previously a 5280 Top Doctor America’s Top Doctors 2015 — Castle Connolly, Medical, Ltd. Recognized in America’s Top Doctors — Castle Connolly, Inc. Best Doctors in America® 2019-2020 — Best Doctors, Inc. Recognized in Best Doctors in America® — Best Doctors, Inc. America’s Top Doctors 2020 — Castle Connolly Medical, Ltd. Email Profile Print Profile Patient Rating 4.7 out of 5 stars 36 Patient Ratings 8 Patient Comments Overview Contact Info & Locations Patient Ratings & Comments Programs & Services Allergy & Asthma Program (Pediatric) Ambulatory Pediatrics Asthma Treatment Programs (Pediatric) Department of Pediatrics Division of Pediatric Pulmonary Medicine Exercise & Performance Breathing Center National Jewish Health for Kids / Pediatric Programs Outpatient Clinic (Pediatric) Pulmonary Diagnostic Center (Pediatric) Respiratory Treatment Programs Severe Asthma Clinic (Pediatric) Spirometry Testing Specialties & Conditions Asthma (Pediatric) Bronchiectasis Overview Bronchopulmonary Dysplasia Central Sleep Apnea Chronic Cough Chronic Respiratory Failure Congenital Anomalies of the Respiratory System Cystic Fibrosis (CF) Interstitial Lung Disease (ILD)/Pulmonary Fibrosis Obstructive Sleep Apnea (OSA) Pneumonia Research Areas Cystic Fibrosis (CF) Asthma (Pediatric) Related Clinical Trials Skin, Airway & Esophageal Epithelial Barriers in Youth Special Interests My main area of expertise is in translational research in cystic fibrosis with a focus on chloride channels, protein chaperones, F508del pathophysiology and protein rescue in CF. I also have a role in pediatric asthma research. I have conducted investigator- initiated trials of 4-phenylbutyrate as a corrector in CF, anti-inflammatories in CF, Adeno-associated Viral gene therapy in CF, and many others. I held the IND for 4-phenylbutyrate for CF and hold the INDs for digitoxin and glycerolphenylbutyrate in CF. I also am a basic science investigator working in the area of chloride channels, proteomics, and protein trafficking. My laboratory is a translational environment where graduate students, clinical fellows, postdoctoral fellows and faculty can work collaboratively to advance our fundamental knowledge about CF airways disease. See More View Publications News & Videos AIR Society Honors Roger A. Silverstein Pamela Zeitlin, MD, PhD, Named Chair of Pediatrics at National Jewish Health Education Education 1976 - 1983 Yale, MD 1976 - 1983 Yale, PhD 1976 - 1980 Yale, MPhil in Cell Biology 1972 - 1976 Stanford University, BS in Biology Internships 1983 - 1984 The Johns Hopkins Hospital, Pediatrics Residency 1984 - 1986 The Johns Hopkins Hospital, Pediatrics Fellowship 1986 - 1988 The Johns Hopkins Hospital, Pediatric Pulmonology Awards & Recognition 2015-2016: Best Doctor's in America - Best Doctor's Inc. 2012: Elizabeth Rich Award, American Thoracic Society 2007: George Will Comstock Award, Maryland Thoracic Society 2006: Maryland Innovator of the Year 1988: Young Investigators' Certificate of Merit, The Johns Hopkins University School of Medicine 1983: Outstanding M.D./Ph.D. Student Award, Yale University 1972: Presidential Scholar for State of Hawaii Board Certification 2006: Recertification, Diplomate Pediatric Pulmonary, 2007-2017 1992: Diplomate of Pediatric Pulmonology, American Board of Pediatrics, recertified 1998 until 2006 1988: American Board of Pediatrics, Permanent Certificate Professional Memberships National Societies: American Association for the Advancement of Science American Thoracic Society (Associate) Chair, Pediatric Assembly (5/2007-5/2009) American College of Chest Physicians (Fellow) American Physiological Society Local Societies: Maryland Lung Association National Scientific Committees: Question Writing Committee, General Pediatrics, American Board of Pediatrics (2013-present) Member, Lung Cellular and Molecular Immunology study section (2008-2012) Gilead Sciences Research Scholars Program review committee (2011) Member, CRRC, NCRR, GCRC study section (2003-2007) Chair-Elect, Subboard of Pediatric Pulmonology, American Board of Pediatrics Chair, Pediatric Program Subcommittee of the American Thoracic Society Subboard of Pediatric Pulmonology, American Board of Pediatrics (1999 - 2005) National Institutes of Health Medical Biochemistry Study Section (1996- 2000) National Institutes of Health, Special Emphasis Panels, Program Project Reviews (1994-96) International Scientific Committees: American Thoracic Society Pediatric Planning Committee (2010-present) American Thoracic Society Pediatric Program Committee Chair Elect (2007) American Thoracic Society Program Review Committee (2004-05) Canadian Cystic Fibrosis Foundation Scientific Review Committee (2000-2003) American Thoracic Society Program Planning Committee (2002) Local Scientific Committees: Maryland Lung Association, Executive Committee (1998-2000) Maryland Lung Association, awards and grant committee (1991-95) Publications Henry KR, Lee S, Walker D, Zeitlin PL. Direct interactions between ENaC gamma subunit and ClCN2 in cystic fibrosis epithelial cells. Physiol Rep. 2015 Jan 27;3(1). pii: e12264. doi: 10.14814/phy2.12264. Print 2015 Jan 1. Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators (Zeitlin PL). Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatr Pulmonol. 2013 Oct;48(10):943-53. Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; for the Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014 May 15. pii: S2213-2600(14)70100-6. In press. Lee S, Henderson MJ, Schiffhauer E, Despanie J, Henry K, Kang PW, Walker D, McClure ML, Wilson L, Sorscher EJ, Zeitlin PL. Interference with ubiquitination in CFTR modifies stability of core glycosylated and cell surface pools. Mol Cell Biol. 2014 Apr 28. [Epub ahead of print] PMCID: PMC4097669. Schiffhauer, E, Vij N, Kovbasnjuk, O, Kang PW, Walker D, Lee S, Zeitlin, PL. Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelial. Am J Physiol Lung Cell Mol Physiol 2013 Mar 1;304(5):L324-31. Teaching & Professional Positions 2001-2016: Professor of Pediatrics, Johns Hopkins University School of Medicine 1994-2001: Associate Professor of Pediatrics, Johns Hopkins University School of Medicine 1989-1994: Assistant Professor of Pediatrics, Johns Hopkins University School of Medicine 1988-1989: Instructor in Pediatrics, Johns Hopkins University School of Medicine Conflicts of Interest National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations. Ask a Question through Patient Portal Sign in to your My National Jewish Health patient portal account to communicate with your care team, manage appointments, and more. Create an Account Contact Information Office: 877.225.5654 Locations National Jewish Health Main Campus 1400 Jackson Street Denver, CO 80206 Patient Ratings The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey. This survey is about the patient care experience and does not address crucial characteristics like medical decision-making, prescribing the best therapy, and patient outcomes. Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey. Provider showed concern 4.7 Friendliness 4.8 Spoke using clear language 4.8 Provider explained things clearly 4.7 Amount of time spent with you 4.7 Provider included you in decisions 4.8 Confidence in your doctor 4.8 Likelihood of recommending this provider 4.7 Comments Comments are collected in our Press Ganey Patient Satisfaction Surveys. Patients are de-identified to protect confidentiality and patient privacy. Learn more about our patient satisfaction survey. National Jewish Health Patient– May, 2021 Best visit - more personable and listened to all my questions. National Jewish Health Patient– March, 2021 All questions were answered. National Jewish Health Patient– March, 2021 Dr. Zeitlin always takes her time to assess/examine [my son] and answer all my questions. I have never felt rushed or unheard, and she is always open to discussion about future treatments/care National Jewish Health Patient– October, 2020 DrZaitlin was great, my son really liked her.Nurse Wendy was also great National Jewish Health Patient– July, 2020 Yes I would've put in higher marks if this was in person but telehealth is a great option during this time National Jewish Health Patient– May, 2020 *Dr. Zeitlin was amazing! She took time to understand our concerns. She also made sure to follow up with all my questions. National Jewish Health Patient– March, 2020 The dr. did not spend enough time with us to hear concerns, did not communicate with us about next steps, and never came back to answer questions. National Jewish Health Patient– January, 2020 Very understanding & helpful.